Isofol Medical AB (publ) (ISOFOL.ST)
SEK 2.53
(3.06%)
SEK 2.53
(3.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -34.41 Million SEK | 74.73% |
| 2022 | -165.7 Million SEK | 18.62% |
| 2021 | -203.62 Million SEK | -25.37% |
| 2020 | -162.41 Million SEK | -10351.48% |
| 2019 | -1.55 Million SEK | -889.81% |
| 2018 | -157 Thousand SEK | -324.29% |
| 2017 | 70 Thousand SEK | -81.38% |
| 2016 | 376 Thousand SEK | 390.83% |
| 2015 | 76.6 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1000.00 SEK | 99.99% |
| 2024 Q1 | -9.67 Million SEK | -967300.0% |
| 2023 Q4 | -1000.00 SEK | 99.1% |
| 2023 FY | -41.87 Million SEK | 74.73% |
| 2023 Q1 | -14.3 Million SEK | 43.86% |
| 2023 Q2 | 14 Thousand SEK | 100.1% |
| 2023 Q3 | -111 Thousand SEK | -892.86% |
| 2022 Q2 | -56.37 Million SEK | -13.83% |
| 2022 FY | -165.7 Million SEK | 18.62% |
| 2022 Q1 | -49.52 Million SEK | 21.2% |
| 2022 Q4 | -25.48 Million SEK | 25.76% |
| 2022 Q3 | -34.32 Million SEK | 39.11% |
| 2021 Q4 | -62.85 Million SEK | -20.36% |
| 2021 FY | -203.62 Million SEK | -25.37% |
| 2021 Q1 | -44.13 Million SEK | -7.15% |
| 2021 Q2 | -44.42 Million SEK | -0.67% |
| 2021 Q3 | -52.21 Million SEK | -17.54% |
| 2020 Q3 | -27.44 Million SEK | 35.47% |
| 2020 Q4 | -41.18 Million SEK | -50.05% |
| 2020 FY | -162.41 Million SEK | -10351.48% |
| 2020 Q1 | -51.24 Million SEK | -17.32% |
| 2020 Q2 | -42.53 Million SEK | 17.01% |
| 2019 FY | -1.55 Million SEK | -889.81% |
| 2019 Q4 | -43.68 Million SEK | -9.89% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | -39.75 Million SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -157 Thousand SEK | -324.29% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q3 | -17.84 Million SEK | -51.71% |
| 2017 FY | 70 Thousand SEK | -81.38% |
| 2017 Q1 | -13.19 Million SEK | 39.8% |
| 2017 Q2 | -11.76 Million SEK | 10.87% |
| 2017 Q4 | -40.61 Million SEK | -127.64% |
| 2016 Q4 | -21.92 Million SEK | -150.62% |
| 2016 Q1 | -14.73 Million SEK | 0.0% |
| 2016 FY | 376 Thousand SEK | 390.83% |
| 2016 Q2 | -10.68 Million SEK | 27.51% |
| 2016 Q3 | -8.74 Million SEK | 18.13% |
| 2015 FY | 76.6 Thousand SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 78.582% |
| Ziccum AB (publ) | -23.28 Million SEK | -47.793% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 109.937% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 182.358% |
| Mendus AB (publ) | 28.48 Million SEK | 220.809% |
| Genovis AB (publ.) | 54 Million SEK | 163.73% |
| Intervacc AB (publ) | -13.79 Million SEK | -149.493% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1685.214% |
| Active Biotech AB (publ) | -1.67 Million SEK | -1954.627% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 445.428% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 228.314% |
| Aptahem AB (publ) | 2.63 Million SEK | 1408.233% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -905.992% |
| Kancera AB (publ) | -1.96 Million SEK | -1651.399% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 44794.805% |
| Fluicell AB (publ) | 1.73 Million SEK | 2080.15% |
| Saniona AB (publ) | 11.78 Million SEK | 392.123% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -572.562% |
| Biovica International AB (publ) | 6.87 Million SEK | 600.436% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -47.812% |
| AcouSort AB (publ) | 8.38 Million SEK | 510.24% |
| Xintela AB (publ) | 78 Thousand SEK | 44221.795% |
| Abliva AB (publ) | -35.66 Million SEK | 3.499% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 76.572% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 1326.042% |
| OncoZenge AB (publ) | 3000.00 SEK | 1147266.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -1683.161% |
| 2cureX AB (publ) | -37.48 Million SEK | 8.195% |
| CombiGene AB (publ) | -21.29 Million SEK | -61.643% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -8035.934% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 103.046% |
| Camurus AB (publ) | 1.58 Billion SEK | 102.177% |
| Corline Biomedical AB | 28.38 Million SEK | 221.265% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 71.96% |
| I-Tech AB | 27.56 Million SEK | 224.846% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 148.505% |
| Cyxone AB (publ) | 2.61 Million SEK | 1418.077% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 1111.314% |
| Biosergen AB | -456 Thousand SEK | -7447.149% |
| Cantargia AB (publ) | -3.45 Million SEK | -897.247% |
| NextCell Pharma AB | -43.74 Million SEK | 21.334% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -274.32% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 406.776% |
| Nanologica AB (publ) | -76 Thousand SEK | -45182.895% |
| SynAct Pharma AB | -778 Thousand SEK | -4323.522% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -17731.606% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -166.329% |
| Lipum AB (publ) | 53 Thousand SEK | 65033.962% |
| BioInvent International AB (publ) | 71.46 Million SEK | 148.159% |
| Alzinova AB (publ) | 19.87 Million SEK | 273.166% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 194.81% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 2452.326% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -229333.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 2175.694% |
| Simris Alg AB (publ) | 2 Million SEK | 1814.748% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -861.313% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 197.25% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -3180.744% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 1198.468% |